Methods and compositions for treating cancer
AssigneeThe Johns Hopkins University
InventorsRichard Markham, James Gordy
Life of this patent
Estimating the term…
Abstract
Provided herein, in some embodiments, are methods and composition for treating cancer in a subject. The methods may include administering to the subject a nucleic acid encoding MIP3α fused to a cancer antigen, administering to the subject a CpG oligodeoxynucleotide, administering to the subject interferon alpha (IFNα), and administering to the subject 5-aza-2′-deoxycytidine (Aza), in effective amounts to treat the cancer.
Claims25
A cancer vaccination method, comprising administering to a subject diagnosed with cancer the following agents, in effective amounts to induce an immune response in the subject:
- (a) a nucleic acid encoding macrophage inflammatory protein-3 alpha (MIP3α) fused to a cancer antigen;
- (b) a CpG oligodeoxynucleotide;
- (c) interferon alpha (IFNα);
- and
- (d) 5-aza-2′-deoxycytidine (Aza).
A composition or kit comprising:
- (a) a nucleic acid encoding macrophage inflammatory protein-3 alpha (MIP3α) fused to a cancer antigen;
- (b) a CpG oligodeoxynucleotide;
- (c) interferon alpha (IFNα);
- (d) 5-aza-2′-deoxycytidine (Aza);
- and
- (e) optionally a pharmaceutically acceptable carrier and/or excipient, wherein (a)-(d) and optionally (e) are formulated for intravenous or intramuscular administration;
- and
- (f) optionally one or more delivery vehicles.
(canceled)
An engineered nucleic acid comprising the sequence of SEQ ID NO:
- 19 or encoding the sequence of SEQ ID NO:
- 20.
(canceled)
Dependencies are inferred from the claim text.